Related Experiment Video
Updated: Apr 16, 2026
Assessing Respiratory Immune Responses to Haemophilus Influenzae
Published on: June 29, 2021
Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now
1Division of Infectious Diseases, Department of Medicine, Clinical and Translational Research Center, Department of Microbiology and Immunology, University at Buffalo, State University of New York, Buffalo, New York, USA murphyt@buffalo.edu.
Insights
Developing a vaccine for nontypeable Haemophilus influenzae is crucial to prevent childhood otitis media and adult COPD infections. Progress is being made toward a broadly effective vaccine to combat these significant global health challenges.
Area of Science:
- Medical Microbiology
- Vaccinology
- Infectious Diseases
Background:
- Nontypeable Haemophilus influenzae (NTHi) causes significant global morbidity, particularly otitis media in children and respiratory tract infections in adults with chronic obstructive pulmonary disease (COPD).
- Recurrent otitis media can lead to hearing loss and developmental delays, while NTHi infections in COPD patients contribute to hospitalizations and respiratory failure.
- The rise in NTHi infections is partly linked to the increased use of pneumococcal conjugate vaccines, highlighting the need for a targeted NTHi vaccine.
Purpose of the Study:
- To review the current landscape of vaccine development for nontypeable Haemophilus influenzae.
- To identify key challenges and promising strategies for creating an effective NTHi vaccine.
- To emphasize the public health importance of preventing NTHi-related diseases.
Main Methods:
- Review of existing literature on NTHi pathogenesis, epidemiology, and vaccine research.
- Analysis of potential vaccine antigens, including surface proteins of H. influenzae.
- Evaluation of the feasibility and progress of NTHi vaccine candidates.
Main Results:
- Partial protection observed with pneumococcal H. influenzae protein D conjugate vaccine demonstrates the potential for NTHi vaccines.
- Several surface proteins of H. influenzae are identified as viable vaccine candidates in various developmental stages.
- Ideal vaccine antigens require conserved surface epitopes, immunogenicity, and the ability to induce protective responses.
Conclusions:
- An effective NTHi vaccine could prevent substantial global morbidity, reduce healthcare costs, and mitigate antibiotic resistance.
- Continued research into conserved surface proteins is expected to yield progress toward a broadly effective NTHi vaccine in the coming years.
- Vaccination against NTHi is a critical strategy for controlling common childhood and adult respiratory infections.
Abstract:
Infections due to nontypeable Haemophilus influenzae result in enormous global morbidity in two clinical settings: otitis media in children and respiratory tract infections in adults with chronic obstructive pulmonary disease (COPD). Recurrent otitis media affects up to 20% of children and results in hearing loss, delays in speech and language development and, in developing countries, chronic suppurative otitis media. Infections in people with COPD result in clinic and emergency room visits, hospital admissions, and respiratory failure. An effective vaccine would prevent morbidity, help control health care costs, and reduce antibiotic use, a major contributor to the global crisis in bacterial antibiotic resistance. The widespread use of the pneumococcal conjugate vaccines is causing a relative increase in H. influenzae otitis media. The partial protection against H. influenzae otitis media induced by the pneumococcal H. influenzae protein D conjugate vaccine represents a proof of principle of the feasibility of a vaccine for nontypeable H. influenzae. An ideal vaccine antigen should be conserved among strains, have abundant epitopes on the bacterial surface, be immunogenic, and induce protective immune responses. Several surface proteins of H. influenzae have been identified as potential vaccine candidates and are in various stages of development. With continued research, progress toward a broadly effective vaccine to prevent infections caused by nontypeable H. influenzae is expected over the next several years.
Related Concept Videos
01:51Vaccinations
01:21Vaccines
01:27Influenza
01:23Vaccine Production
01:28Diphtheria
01:29Microorganisms in Medicine and Therapeutics